Announcements Trials
Browse Landscape

Phase

Phase NA 72Phase 1 43Phase 2 39Phase 1/2 21Phase 3 7Phase 4 4Phase EARLY_PHASE1 3Phase 2/3 3

Status

Active not recruiting 6Not yet recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 7

Conditions

Breast Neoplasms 245Carcinoma, Non-Small-Cell Lung 225Prostatic Neoplasms 113Neoplasms 104Multiple Myeloma 90Neoplasm Metastasis 75Colorectal Neoplasms 73Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 66Ovarian Neoplasms 61Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 47Melanoma 46Leukemia, Lymphocytic, Chronic, B-Cell 44Carcinoma, Renal Cell 43Urinary Bladder Neoplasms 41Stomach Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Triple Negative Breast Neoplasms 40Recurrence 40Brain Neoplasms 40Myasthenia Gravis 37Small Cell Lung Carcinoma 35Lymphoma, Follicular 35Nasopharyngeal Carcinoma 34Head and Neck Neoplasms 33Pancreatic Neoplasms 32Rectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 30Colonic Neoplasms 29

Interventions

durvalumab 4Bevacizumab 3tremelimumab 2lenvatinib 1atezolizumab 1Nivolumab 1Analgesia, Patient-Controlled 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × Liver Neoplasms × 1 year × Clear all
NCT05883644 2026-04-30

SIERRA

AstraZeneca

Phase 3 Active not recruiting
111 enrolled
Gastrointestinal

Liver Neoplasms

NCT03778957 2026-04-15

EMERALD-1

AstraZeneca

Phase 3 Active not recruiting
724 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05301842 2026-04-07

EMERALD-3

AstraZeneca

Phase 3 Active not recruiting
760 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03847428 2026-03-06

EMERALD-2

AstraZeneca

Phase 3 Active not recruiting
908 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03383458 2025-11-21

CheckMate 9DX

Bristol-Myers Squibb

Phase 3 Active not recruiting
545 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06680258 2025-09-03

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Tempest Therapeutics

Phase 3 Not yet recruiting
740 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

NCT02523443 2025-07-22

Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection

Memorial Sloan Kettering Cancer Center

Phase 3 Active not recruiting
231 enrolled
Gastrointestinal

Agnosia, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡